Ustekinumab is a human monoclonal antibody used to treat psoriasis, psoraitic arthritis and Crohn’s disease.
It blocks interleukin IL-12 and IL-23, which help activate certain T-cells, by binding to the p-40 subunit of both IL-12 and IL-23 so that they subsequently cannot bind to their receptors.
It is administered through subcutaneous injection every 8 weeks.
In 2016, it sold €572 million in Europe.
It has an immunogenicity rate of 1-11%.
Labs that test for drug level:
Labs that test for ADA titre: